IPO Landscape: Surging SPACs and a Pandemic Boom Ahead
This report analyzes key aspects of initial public offerings for technology and life sciences companies that went public in 2020 and an outlook of the year ahead.Read More
Leveraging more than 25 years of experience, Rob provides a wide range of corporate and securities legal services to innovative late-stage and public companies in the life sciences and technology industries. He represents issuers and underwriters in going public transactions, including IPOs, SPACs, reverse mergers, direct listings, as well as in follow-on offerings and private placements of equity and debt securities. Rob also advises boards and management as an outside general counsel on day-to-day corporate and securities matters, including corporate governance, public company reporting, and stock exchange rules and requirements.
Rob co-chairs Fenwick’s capital markets and public companies group, helping clients raise capital, navigate risk, and tell a story through filings and disclosures over the long term. For example, he represented Loxo Oncology in its IPO, multiple follow-on offerings and its $8 billion acquisition by Eli Lilly. He has also represented Dexcom, a leader in continuous glucose monitoring, for more than 15 years, from its IPO in 2005 to numerous public and private offerings of equity and debt. Rob is committed to a company’s myriad legal needs through its full lifecycle.
Ranked as a top capital markets lawyer by Chambers USA and Chambers Global, Rob is regularly sought after for his thought leadership. He is a lead author of the firm’s Technology and Life Sciences IPO Survey and co-chairs the Practising Law Institute’s How to Prepare an Initial Public Offering 2019 program.
Clients praise Rob’s “very good technical skill set, terrific work and very up-to-date advice on complex capital markets transactions.”
J.D., with distinction, Stanford Law School
A.B., summa cum laude, Biochemistry and History
Phi Beta Kappa
Admitted to practice in California, Idaho and Washington